Academia.eduAcademia.edu

Outline

Title
Abstract
Introduction
Future Directions
References
All Topics
Biology
Physiology

Macropinocytosis, mTORC1 and cellular growth control

Profile image of Joel A SwansonJoel A Swanson

2018, Cellular and molecular life sciences : CMLS

https://doi.org/10.1007/S00018-017-2710-Y
visibility

…

description

13 pages

link

1 file

Abstract

The growth and proliferation of metazoan cells are driven by cellular nutrient status and by extracellular growth factors. Growth factor receptors on cell surfaces initiate biochemical signals that increase anabolic metabolism and macropinocytosis, an actin-dependent endocytic process in which relatively large volumes of extracellular solutes and nutrients are internalized and delivered efficiently into lysosomes. Macropinocytosis is prominent in many kinds of cancer cells, and supports the growth of cells transformed by oncogenic K-Ras. Growth factor receptor signaling and the overall metabolic status of the cell are coordinated in the cytoplasm by the mechanistic target-of-rapamycin complex-1 (mTORC1), which positively regulates protein synthesis and negatively regulates molecular salvage pathways such as autophagy. mTORC1 is activated by two distinct Ras-related small GTPases, Rag and Rheb, which associate with lysosomal membranes inside the cell. Rag recruits mTORC1 to the lysos...

Related papers

mTOR Pathways in Cancer and Autophagy
Arnim Pause

Cancers

TOR (target of rapamycin), an evolutionarily-conserved serine/threonine kinase, acts as a central regulator of cell growth, proliferation and survival in response to nutritional status, growth factor, and stress signals. It plays a crucial role in coordinating the balance between cell growth and cell death, depending on cellular conditions and needs. As such, TOR has been identified as a key modulator of autophagy for more than a decade, and several deregulations of this pathway have been implicated in a variety of pathological disorders, including cancer. At the molecular level, autophagy regulates several survival or death signaling pathways that may decide the fate of cancer cells; however, the relationship between autophagy pathways and cancer are still nascent. In this review, we discuss the recent cellular signaling pathways regulated by TOR, their interconnections to autophagy, and the clinical implications of TOR inhibitors in cancer.

View PDFchevron_right
A Tumor Suppressor Complex with GAP Activity for the Rag GTPases That Signal Amino Acid Sufficiency to mTORC1
Scott Carter

Science, 2013

The mTOR Complex 1 (mTORC1) pathway promotes cell growth in response to many cues, including amino acids, which act through the Rag GTPases to promote mTORC1 translocation to the lysosomal surface, its site of activation. Although progress has been made in identifying positive regulators of the Rags, it is unknown if negative factors also exist. Here, we identify GATOR as a complex that interacts with the Rags and is composed of two subcomplexes we call GATOR1 and 2. Inhibition of GATOR1 subunits (DEPDC5, Nprl2, and Nprl3) makes mTORC1 signaling resistant to amino acid deprivation. In contrast, inhibition of GATOR2 subunits (Mios, WDR24, WDR59, Seh1L, Sec13) suppresses mTORC1 signaling and epistasis analysis shows that GATOR2 negatively regulates DEPDC5. GATOR1 has GTPase activating protein (GAP) activity for RagA and RagB and its components are mutated in human cancer. In cancer cells with inactivating mutations in GATOR1, mTORC1 is hyperactive and insensitive to amino acid starvation and such cells are hypersensitive to rapamycin, an mTORC1 inhibitor. Thus, we identify a key negative regulator of the Rag GTPases and reveal that, like other mTORC1 regulators, Rag function can be deregulated in cancer.

View PDFchevron_right
CIP2A oncoprotein controls cell growth and autophagy through mTORC1 activation
M. Jäättelä

The Journal of Cell Biology, 2014

View PDFchevron_right
Nutrient-dependent regulation of autophagy through the target of rapamycin pathway
Gábor Juhász

Biochemical Society Transactions - BIOCHEM SOC TRANS, 2009

In response to nutrient deficiency, eukaryotic cells activate macroautophagy, a degradative process in which proteins, organelles and cytoplasm are engulfed within unique vesicles called autophagosomes. Fusion of these vesicles with the endolysosomal compartment leads to breakdown of the sequestered material into amino acids and other simple molecules, which can be used as nutrient sources during periods of starvation. This process is driven by a group of autophagy-related (Atg) proteins, and is suppressed by TOR (target of rapamycin) signalling under favourable conditions. Several distinct kinase complexes have been implicated in autophagic signalling downstream of TOR. In yeast, TOR is known to control autophagosome formation in part through a multiprotein complex containing the serine/threonine protein kinase Atg1. Recent work in Drosophila and mammalian systems suggest that this complex and its regulation by TOR are conserved in higher eukaryotes, and that Atg1 has accrued additional functions including feedback regulation of TOR itself. TOR and Atg1 also control the activity of a second kinase complex containing Atg6/Beclin 1, Vps (vacuolar protein sorting) 15 and the class III PI3K (phosphoinositide 3-kinase) Vps34. During autophagy induction, Vps34 activity is mobilized from an early endosomal compartment to nascent autophagic membranes, in a TOR-and Atg1-responsive manner. Finally, the well-known TOR substrate S6K (p70 ribosomal protein S6 kinase) has been shown to play a positive role in autophagy, which may serve to limit levels of autophagy under conditions of continuously low TOR activity. Further insight into these TOR-dependent control mechanisms may support development of autophagy-based therapies for a number of pathological conditions. Key words: autophagy-related gene 1/Unc51-like kinase 1 (Atg1/Ulk1), autophagy, cell growth, Drosophila, target of rapamycin (TOR), vacuolar protein sorting 34 (Vps34). Abbreviations used: Atg, autophagy-related gene; ESCRT, endosomal sorting complex required for transport; PI3K, phosphoinositide 3-kinase; S6K, p70 ribosomal protein S6 kinase; TOR, target of rapamycin; Ulk1, Unc51-like kinase 1; Vps, vacuolar protein sorting.

View PDFchevron_right
Macropinocytosis drives T cell growth by sustaining the activation of mTORC1
Joel A Swanson

Nature Communications

Macropinocytosis is an evolutionarily-conserved, large-scale, fluid-phase form of endocytosis that has been ascribed different functions including antigen presentation in macrophages and dendritic cells, regulation of receptor density in neurons, and regulation of tumor growth under nutrient-limiting conditions. However, whether macropinocytosis regulates the expansion of non-transformed mammalian cells is unknown. Here we show that primary mouse and human T cells engage in macropinocytosis that increases in magnitude upon T cell activation to support T cell growth even under amino acid (AA) replete conditions. Mechanistically, macropinocytosis in T cells provides access of extracellular AA to an endolysosomal compartment to sustain activation of the mechanistic target of rapamycin complex 1 (mTORC1) that promotes T cell growth. Our results thus implicate a function of macropinocytosis in mammalian cell growth beyond Ras-transformed tumor cells via sustained mTORC1 activation.

View PDFchevron_right
Activated Ras requires autophagy to maintain oxidative metabolism and tumorigenesis
Hy chen

Genes & Development, 2011

Autophagy is a catabolic pathway used by cells to support metabolism in response to starvation and to clear damaged proteins and organelles in response to stress. We report here that expression of a H-rasV12 or K-rasV12 oncogene up-regulates basal autophagy, which is required for tumor cell survival in starvation and in tumorigenesis. In Ras-expressing cells, defective autophagosome formation or cargo delivery causes accumulation of abnormal mitochondria and reduced oxygen consumption. Autophagy defects also lead to tricarboxylic acid (TCA) cycle metabolite and energy depletion in starvation. As mitochondria sustain viability of Ras-expressing cells in starvation, autophagy is required to maintain the pool of functional mitochondria necessary to support growth of Ras-driven tumors. Human cancer cell lines bearing activating mutations in Ras commonly have high levels of basal autophagy, and, in a subset of these, down-regulating the expression of essential autophagy proteins impaired...

View PDFchevron_right
Synergistic effect of targeting mTOR by rapamycin and depleting ATP by inhibition of glycolysis in lymphoma and leukemia cells
H. Pelicano

Leukemia, 2005

The mammalian target of rapamycin (mTOR) pathway plays important roles in regulating nutrient metabolism and promoting the growth and survival of cancer cells, which exhibit increased glycolysis for ATP generation. In this study, we tested the hypothesis that inhibition of the mTOR pathway and glycolysis would synergistically impact the energy metabolism in cancer cells and may serve as an effective therapeutic strategy to kill malignant cells. Using human lymphoma cells and leukemia cells, we demonstrated that the combination of rapamycin, an mTOR inhibitor, with a glycolytic inhibitor produced synergistic cytotoxic effect, as evidenced by apoptosis and cell growth inhibition assays. Mechanistic studies showed that inhibition of the mTOR pathway by rapamycin alone sufficiently suppressed the phosphorylation of the downstream molecules p70S6K and 4E-BP-1, but only caused a moderate cytostatic effect. Combination of mTOR inhibition and blockage of glycolysis synergistically suppressed glucose uptake and severely depleted cellular ATP pools, leading to significant enhancement of cell killing. In contrast, combination of rapamycin and ara-C did not increase cytotoxicity in vitro. Our findings suggest that targeting mTOR pathway in combination with inhibition of glycolysis may be an effective therapeutic strategy for hematological malignancies. This mechanismbased drug combination warrants further investigation in preclinical and clinical settings.

View PDFchevron_right
mTORC2 controls cancer cell survival by modulating gluconeogenesis
Dipsikha Biswas

Cell Death Discovery, 2015

For rapid tumor growth, cancer cells often reprogram the cellular metabolic processes to obtain enhanced anabolic precursors and energy. The molecular changes of such metabolic rewiring are far from established. Here we explored the role of mTOR (mechanistic target of rapamycin), which serves as a key regulator of cell growth, proliferation and survival, in the metabolic reprograming of cancer cells. When we inhibited mTOR in human hepatocellular carcinoma (HCC) and renal cell carcinoma (RCC) cells, using pharmacologic inhibitors or by RNA interference, we noticed shuttle of the glycolytic flux to gluconeogenesis pathway along with reduction in cellular proliferation and survival. Augmentation of gluconeogenesis was mechanistically linked to upregulation of the key gluconeogenic enzymes PCK1 and G6PC expressions, enhanced lactate dehydrogenase activity and glucose-derived lipogenesis without causing any attenuation in mitochondrial function. Interestingly, concomitant knocking down ...

View PDFchevron_right
Rapamycin Plus Doxycycline Combination Affects Growth Arrest and Selective Autophagy-Dependent Cell Death in Breast Cancer Cells
Gábor Barna

International Journal of Molecular Sciences, 2021

Metabolic alteration is characteristic during tumour growth and therapy; however, targeting metabolic rewiring could overcome therapy resistance. mTOR hyperactivity, autophagy and other metabolic processes, including mitochondrial functions, could be targeted in breast cancer progression. We investigated the growth inhibitory mechanism of rapamycin + doxycycline treatment in human breast cancer model systems. Cell cycle and cell viability, including apoptotic and necrotic cell death, were analysed using flow cytometry, caspase activity measurements and caspase-3 immunostainings. mTOR-, autophagy-, necroptosis-related proteins and treatment-induced morphological alterations were analysed by WesTM, Western blot, immunostainings and transmission electron microscopy. The rapamycin + doxycycline combination decreased tumour proliferation in about 2/3rd of the investigated cell lines. The continuous treatment reduced tumour growth significantly both in vivo and in vitro. The effect after ...

View PDFchevron_right
Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression
Diane Fingar

Oncogene, 2004

Cell growth (an increase in cell mass and size through macromolecular biosynthesis) and cell cycle progression are generally tightly coupled, allowing cells to proliferate continuously while maintaining their size. The target of rapamycin (TOR) is an evolutionarily conserved kinase that integrates signals from nutrients (amino acids and energy) and growth factors (in higher eukaryotes) to regulate cell growth and cell cycle progression coordinately. In mammals, TOR is best known to regulate translation through the ribosomal protein S6 kinases (S6Ks) and the eukaryotic translation initiation factor 4Ebinding proteins. Consistent with the contribution of translation to growth, TOR regulates cell, organ, and organismal size. The identification of tumor suppressor protein tuberous sclerosis1/2 and Ras-homolog enriched in brain has biochemically linked the TOR and phosphatidylinositol 3-kinase (PI3K) pathways, providing a mechanism for the crosstalk that occurs between these pathways. TOR is emerging as a novel antitumor target, since the TOR inhibitor rapamycin appears to be effective against tumors resulting from aberrantly high PI3K signaling. Not only may inhibition of TOR be effective in cancer treatment, but rapamycin is an FDA-approved immunosuppressive and cardiology drug. We review here what is known (and not known) about the function of TOR in cellular and animal physiology.

View PDFchevron_right

References (123)

  1. Swanson JA (2008) Shaping cups into phagosomes and macro- pinosomes. Nat Rev Mol Cell Biol 9(8):639-649
  2. Bloomfield G, Kay RR (2016) Uses and abuses of macropino- cytosis. J Cell Sci 129(14):2697-2705. https://doi.org/10.1242/ jcs.176149
  3. Lewis WH (1931) Pinocytosis. B Johns Hopkins Hosp 49:17-27
  4. Cohn ZA, Parks E (1967) The regulation of pinocytosis in mouse macrophages. IV. The immunological induction of pinocytic vesicles, secondary lysosomes, and hydrolytic enzymes. J Exp Med 125(6):1091-1104
  5. Amyere M, Payrastre B, Krause U, Van Der Smissen P, Veithen A, Courtoy PJ (2000) Constitutive macropinocytosis in onco- gene-transformed fibroblasts depends on sequential permanent activation of phosphoinositide 3-kinase and phospholipase C. Mol Biol Cell 11(10):3453-3467
  6. Veithen A, Cupers P, Baudhuin P, Courtoy PJ (1996) v-Src induces constitutive macropinocytosis in rat fibroblasts. J Cell Sci 109(Pt 8):2005-2012
  7. Commisso C, Davidson SM, Soydaner-Azeloglu RG, Parker SJ, Kamphorst JJ, Hackett S, Grabocka E, Nofal M, Drebin JA, Thompson CB, Rabinowitz JD, Metallo CM, Vander Hei- den MG, Bar-Sagi D (2013) Macropinocytosis of protein is an amino acid supply route in Ras-transformed cells. Nature 497(7451):633-637. https://doi.org/10.1038/nature12138
  8. Palm W, Park Y, Wright K, Pavlova NN, Tuveson DA, Thompson CB (2015) The utilization of extracellular proteins as nutrients is suppressed by mTORC1. Cell 162(2):259-270. https://doi. org/10.1016/j.cell.2015.06.017
  9. Zeineddine R, Yerbury JJ (2015) The role of macropinocytosis in the propagation of protein aggregation associated with neurode- generative diseases. Front Physiol 6:277. https://doi.org/10.3389/ fphys.2015.00277
  10. Kruth HS, Jones NL, Huang W, Zhao B, Ishii I, Chang J, Combs CA, Malide D, Zhang WY (2005) Macropinocytosis is the endo- cytic pathway that mediates macrophage foam cell formation with native low density lipoprotein. J Biol Chem 280(3):2352- 2360. https://doi.org/10.1074/jbc.M407167200
  11. Chung JJ, Huber TB, Godel M, Jarad G, Hartleben B, Kwoh C, Keil A, Karpitskiy A, Hu J, Huh CJ, Cella M, Gross RW, Miner JH, Shaw AS (2015) Albumin-associated free fatty acids induce macropinocytosis in podocytes. J Clin Investig 125(6):2307- 2316. https://doi.org/10.1172/JCI79641
  12. Heitman J, Movva NR, Hall MN (1991) Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast. Science 253(5022):905-909
  13. Sabatini DM, Erdjument-Bromage H, Lui M, Tempst P, Snyder SH (1994) RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs. Cell 78(1):35-43
  14. Sabers CJ, Martin MM, Brunn GJ, Williams JM, Dumont FJ, Wiederrecht G, Abraham RT (1995) Isolation of a protein target of the FKBP12-rapamycin complex in mammalian cells. J Biol Chem 270(2):815-822
  15. Zoncu R, Efeyan A, Sabatini DM (2011) mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol 12(1):21-35. https://doi.org/10.1038/nrm3025
  16. Jacinto E, Loewith R, Schmidt A, Lin S, Ruegg MA, Hall A, Hall MN (2004) Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat Cell Biol 6(11):1122-1128
  17. Sarbassov DD, Ali SM, Kim DH, Guertin DA, Latek RR, Erd- jument-Bromage H, Tempst P, Sabatini DM (2004) Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskel- eton. Curr Biol 14(14):1296-1302. https://doi.org/10.1016/j. cub.2004.06.054
  18. Kim DH, Sarbassov DD, Ali SM, King JE, Latek RR, Erdjument- Bromage H, Tempst P, Sabatini DM (2002) mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell 110(2):163-175
  19. Hara K, Maruki Y, Long X, Yoshino K, Oshiro N, Hidayat S, Tokunaga C, Avruch J, Yonezawa K (2002) Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. Cell 110(2):177-189
  20. Loewith R, Jacinto E, Wullschleger S, Lorberg A, Crespo JL, Bonenfant D, Oppliger W, Jenoe P, Hall MN (2002) Two TOR complexes, only one of which is rapamycin sensitive, have dis- tinct roles in cell growth control. Mol Cell 10(3):457-468
  21. Peterson TR, Laplante M, Thoreen CC, Sancak Y, Kang SA, Kuehl WM, Gray NS, Sabatini DM (2009) DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival. Cell 137(5):873-886. https://doi. org/10.1016/j.cell.2009.03.046
  22. Vander Haar E, Lee SI, Bandhakavi S, Griffin TJ, Kim DH (2007) Insulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40. Nat Cell Biol 9(3):316-323. https://doi.org/10.1038/ ncb1547
  23. Sancak Y, Thoreen CC, Peterson TR, Lindquist RA, Kang SA, Spooner E, Carr SA, Sabatini DM (2007) PRAS40 is an insulin- regulated inhibitor of the mTORC1 protein kinase. Mol Cell 25(6):903-915. https://doi.org/10.1016/j.molcel.2007.03.003
  24. Oshiro N, Takahashi R, Yoshino K, Tanimura K, Nakashima A, Eguchi S, Miyamoto T, Hara K, Takehana K, Avruch J, Kikkawa U, Yonezawa K (2007) The proline-rich Akt substrate of 40 kDa (PRAS40) is a physiological substrate of mammalian target of rapamycin complex 1. J Biol Chem 282(28):20329-20339. https://doi.org/10.1074/jbc.M702636200
  25. Yang Q, Inoki K, Ikenoue T, Guan KL (2006) Identification of Sin1 as an essential TORC2 component required for complex formation and kinase activity. Genes Dev 20(20):2820-2832. https://doi.org/10.1101/gad.1461206
  26. Frias MA, Thoreen CC, Jaffe JD, Schroder W, Sculley T, Carr SA, Sabatini DM (2006) mSin1 is necessary for Akt/PKB phos- phorylation, and its isoforms define three distinct mTORC2s. Curr Biol 16(18):1865-1870. https://doi.org/10.1016/j. cub.2006.08.001
  27. Pearce LR, Huang X, Boudeau J, Pawlowski R, Wullschleger S, Deak M, Ibrahim AF, Gourlay R, Magnuson MA, Alessi DR (2007) Identification of Protor as a novel Rictor-binding compo- nent of mTOR complex-2. Biochem J 405(3):513-522. https:// doi.org/10.1042/BJ20070540
  28. Efeyan A, Zoncu R, Sabatini DM (2012) Amino acids and mTORC1: from lysosomes to disease. Trends Mol Med 18(9):524-533. https://doi.org/10.1016/j.molmed.2012.05.007
  29. Cornu M, Albert V, Hall MN (2013) mTOR in aging, metabo- lism, and cancer. Curr Opin Genet Dev 23(1):53-62. https://doi. org/10.1016/j.gde.2012.12.005
  30. Jewell JL, Guan KL (2013) Nutrient signaling to mTOR and cell growth. Trends Biochem Sci 38(5):233-242. https://doi. org/10.1016/j.tibs.2013.01.004
  31. Mendoza MC, Er EE, Blenis J (2011) The Ras-ERK and PI3K- mTOR pathways: cross-talk and compensation. Trends Biochem Sci 36(6):320-328. https://doi.org/10.1016/j.tibs.2011.03.006
  32. Dibble CC, Manning BD (2013) Signal integration by mTORC1 coordinates nutrient input with biosynthetic output. Nat Cell Biol 15(6):555-564. https://doi.org/10.1038/ncb2763
  33. Bar-Peled L, Sabatini DM (2014) Regulation of mTORC1 by amino acids. Trends Cell Biol 24(7):400-406. https://doi. org/10.1016/j.tcb.2014.03.003
  34. Saxton RA, Sabatini DM (2017) mTOR signaling in growth, metabolism, and disease. Cell 168(6):960-976
  35. Yao Y, Inoki K (2016) The role of mechanistic target of rapa- mycin in maintenance of glomerular epithelial cells. Curr Opin Nephrol Hypertens 25(1):28-34. https://doi.org/10.1097/ MNH.0000000000000181
  36. Kurdi A, De Meyer GR, Martinet W (2016) Potential therapeutic effects of mTOR inhibition in atherosclerosis. Br J Clin Pharma- col 82(5):1267-1279. https://doi.org/10.1111/bcp.12820
  37. Perluigi M, Di Domenico F, Butterfield DA (2015) mTOR sign- aling in aging and neurodegeneration: at the crossroad between metabolism dysfunction and impairment of autophagy. Neuro- biol Dis 84:39-49. https://doi.org/10.1016/j.nbd.2015.03.014
  38. Pacitto R, Gaeta I, Swanson JA, Yoshida S (2017) CXCL12- induced macropinocytosis modulates two distinct pathways to activate mTORC1 in macrophages. J Leukoc Biol 101:683- 692. https://doi.org/10.1189/jlb.2A0316-141RR
  39. Zwartkruis FJ, Burgering BM (2013) Ras and macropino- cytosis: trick and treat. Cell Res 23(8):982-983. https://doi. org/10.1038/cr.2013.79
  40. Yoshida S, Pacitto R, Yao Y, Inoki K, Swanson JA (2015) Growth factor signaling to mTORC1 by amino acid-laden macropinosomes. J Cell Biol 211(1):159-172. https://doi. org/10.1083/jcb.201504097
  41. Sung S, Choi J, Cheong H (2015) Catabolic pathways regu- lated by mTORC1 are pivotal for survival and growth of cancer cells expressing mutant Ras. Oncotarget 6(38):40405-40417. https://doi.org/10.18632/oncotarget.6334
  42. Cheong H (2016) mTORC1 regulates nutrient access in Ras-mediated tumors. Aging 8(6):1165-1166. https://doi. org/10.18632/aging.100974
  43. Saito K, Araki Y, Kontani K, Nishina H, Katada T (2005) Novel role of the small GTPase Rheb: its implication in endo- cytic pathway independent of the activation of mammalian target of rapamycin. J Biochem 137(3):423-430. https://doi. org/10.1093/jb/mvi046
  44. Sancak Y, Bar-Peled L, Zoncu R, Markhard AL, Nada S, Sabatini DM (2010) Ragulator-Rag complex targets mTORC1 to the lysosomal surface and is necessary for its activation by amino acids. Cell 141(2):290-303. https://doi.org/10.1016/j. cell.2010.02.024
  45. Betz C, Hall MN (2013) Where is mTOR and what is it doing there? J Cell Biol 203(4):563-574. https://doi.org/10.1083/ jcb.201306041
  46. Bar-Peled L, Schweitzer LD, Zoncu R, Sabatini DM (2012) Ragulator is a GEF for the rag GTPases that signal amino acid levels to mTORC1. Cell 150(6):1196-1208. https://doi. org/10.1016/j.cell.2012.07.032
  47. Zoncu R, Bar-Peled L, Efeyan A, Wang S, Sancak Y, Sabatini DM (2011) mTORC1 senses lysosomal amino acids through an inside-out mechanism that requires the vacuolar H(+)- ATPase. Science 334(6056):678-683. https://doi.org/10.1126/ science.1207056
  48. Wang S, Tsun ZY, Wolfson RL, Shen K, Wyant GA, Plovanich ME, Yuan ED, Jones TD, Chantranupong L, Comb W, Wang T, Bar-Peled L, Zoncu R, Straub C, Kim C, Park J, Sabatini BL, Sabatini DM (2015) Metabolism. Lysosomal amino acid transporter SLC38A9 signals arginine sufficiency to mTORC1. Science 347(6218):188-194. https://doi.org/10.1126/ science.1257132
  49. Rebsamen M, Pochini L, Stasyk T, de Araujo ME, Galluccio M, Kandasamy RK, Snijder B, Fauster A, Rudashevskaya EL, Bruckner M, Scorzoni S, Filipek PA, Huber KV, Bigenzahn JW, Heinz LX, Kraft C, Bennett KL, Indiveri C, Huber LA, Superti- Furga G (2015) SLC38A9 is a component of the lysosomal amino acid sensing machinery that controls mTORC1. Nature 519(7544):477-481. https://doi.org/10.1038/nature14107
  50. Jung J, Genau HM, Behrends C (2015) Amino acid-depend- ent mTORC1 regulation by the lysosomal membrane pro- tein SLC38A9. Mol Cell Biol 35(14):2479-2494. https://doi. org/10.1128/MCB.00125-15
  51. Wyant GA, Abu-Remaileh M, Wolfson RL, Chen WW, Freink- man E, Danai LV, Vander Heiden MG, Sabatini DM (2017) mTORC1 activator SLC38A9 is required to efflux essential amino acids from lysosomes and use protein as a nutrient. Cell 171(3):642-654 e612. https://doi.org/10.1016/j.cell.2017.09.046
  52. Hallett JE, Manning BD (2016) CASTORing new light on amino acid sensing. Cell 165(1):15-17. https://doi.org/10.1016/j. cell.2016.03.002
  53. Bar-Peled L, Chantranupong L, Cherniack AD, Chen WW, Ottina KA, Grabiner BC, Spear ED, Carter SL, Meyerson M, Sabatini DM (2013) A Tumor suppressor complex with GAP activity for the Rag GTPases that signal amino acid sufficiency to mTORC1. Science 340(6136):1100-1106. https://doi.org/10.1126/ science.1232044
  54. Chantranupong L, Wolfson RL, Orozco JM, Saxton RA, Scaria SM, Bar-Peled L, Spooner E, Isasa M, Gygi SP, Sabatini DM (2014) The sestrins interact with GATOR2 to negatively regulate the amino-acid-sensing pathway upstream of mTORC1. Cell Rep 9(1):1-8. https://doi.org/10.1016/j.celrep.2014.09.014
  55. Peng M, Yin N, Li MO (2014) Sestrins function as guanine nucleotide dissociation inhibitors for Rag GTPases to con- trol mTORC1 signaling. Cell 159(1):122-133. https://doi. org/10.1016/j.cell.2014.08.038
  56. Wolfson RL, Chantranupong L, Saxton RA, Shen K, Scaria SM, Cantor JR, Sabatini DM (2016) Sestrin2 is a leucine sensor for the mTORC1 pathway. Science 351(6268):43-48. https://doi. org/10.1126/science.aab2674
  57. Chantranupong L, Scaria SM, Saxton RA, Gygi MP, Shen K, Wyant GA, Wang T, Harper JW, Gygi SP, Sabatini DM (2016) The CASTOR proteins are arginine sensors for the mTORC1 pathway. Cell 165(1):153-164. https://doi.org/10.1016/j. cell.2016.02.035
  58. Jewell JL, Kim YC, Russell RC, Yu FX, Park HW, Plouffe SW, Tagliabracci VS, Guan KL (2015) Metabolism. Differen- tial regulation of mTORC1 by leucine and glutamine. Science 347(6218):194-198. https://doi.org/10.1126/science.1259472
  59. Nicklin P, Bergman P, Zhang B, Triantafellow E, Wang H, Nyfeler B, Yang H, Hild M, Kung C, Wilson C, Myer VE, MacK- eigan JP, Porter JA, Wang YK, Cantley LC, Finan PM, Mur- phy LO (2009) Bidirectional transport of amino acids regulates mTOR and autophagy. Cell 136(3):521-534
  60. Duran RV, Oppliger W, Robitaille AM, Heiserich L, Skendaj R, Gottlieb E, Hall MN (2012) Glutaminolysis activates Rag- mTORC1 signaling. Mol Cell 47(3):349-358
  61. Sancak Y, Peterson TR, Shaul YD, Lindquist RA, Thoreen CC, Bar-Peled L, Sabatini DM (2008) The Rag GTPases bind raptor and mediate amino acid signaling to mTORC1. Science 320(5882):1496-1501. https://doi.org/10.1126/science.1157535
  62. Saucedo LJ, Gao X, Chiarelli DA, Li L, Pan D, Edgar BA (2003) Rheb promotes cell growth as a component of the insulin/TOR signalling network. Nat Cell Biol 5(6):566-571. https://doi. org/10.1038/ncb996
  63. Stocker H, Radimerski T, Schindelholz B, Wittwer F, Belawat P, Daram P, Breuer S, Thomas G, Hafen E (2003) Rheb is an essen- tial regulator of S6K in controlling cell growth in Drosophila. Nat Cell Biol 5(6):559-565. https://doi.org/10.1038/ncb995
  64. Menon S, Dibble CC, Talbott G, Hoxhaj G, Valvezan AJ, Taka- hashi H, Cantley LC, Manning BD (2014) Spatial control of the TSC complex integrates insulin and nutrient regulation of mTORC1 at the lysosome. Cell 156(4):771-785. https://doi. org/10.1016/j.cell.2013.11.049
  65. Inoki K, Li Y, Xu T, Guan KL (2003) Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signal- ing. Genes Dev 17(15):1829-1834. https://doi.org/10.1101/ gad.1110003
  66. Garami A, Zwartkruis FJ, Nobukuni T, Joaquin M, Roccio M, Stocker H, Kozma SC, Hafen E, Bos JL, Thomas G (2003) Insu- lin activation of Rheb, a mediator of mTOR/S6K/4E-BP signal- ing, is inhibited by TSC1 and 2. Mol Cell 11(6):1457-1466
  67. Zhang Y, Gao X, Saucedo LJ, Ru B, Edgar BA, Pan D (2003) Rheb is a direct target of the tuberous sclerosis tumour suppres- sor proteins. Nat Cell Biol 5(6):578-581. https://doi.org/10.1038/ ncb999
  68. Inoki K, Li Y, Zhu T, Wu J, Guan KL (2002) TSC2 is phospho- rylated and inhibited by Akt and suppresses mTOR signalling. Nat Cell Biol 4(9):648-657. https://doi.org/10.1038/ncb839
  69. Potter CJ, Pedraza LG, Xu T (2002) Akt regulates growth by directly phosphorylating Tsc2. Nat Cell Biol 4(9):658-665. https://doi.org/10.1038/ncb840
  70. Manning BD, Tee AR, Logsdon MN, Blenis J, Cantley LC (2002) Identification of the tuberous sclerosis complex-2 tumor sup- pressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway. Mol Cell 10(1):151-162
  71. Roux PP, Ballif BA, Anjum R, Gygi SP, Blenis J (2004) Tumor- promoting phorbol esters and activated Ras inactivate the tuber- ous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase. Proc Natl Acad Sci USA 101(37):13489-13494. https:// doi.org/10.1073/pnas.0405659101
  72. Dibble CC, Cantley LC (2015) Regulation of mTORC1 by PI3K signaling. Trends Cell Biol 25(9):545-555. https://doi. org/10.1016/j.tcb.2015.06.002
  73. Benjamin D, Hall MN (2014) mTORC1: turning off is just as important as turning on. Cell 156(4):627-628. https://doi. org/10.1016/j.cell.2014.01.057
  74. Demetriades C, Doumpas N, Teleman AA (2014) Regula- tion of TORC1 in response to amino acid starvation via lyso- somal recruitment of TSC2. Cell 156(4):786-799. https://doi. org/10.1016/j.cell.2014.01.024
  75. Carroll B, Maetzel D, Maddocks OD, Otten G, Ratcliff M, Smith GR, Dunlop EA, Passos JF, Davies OR, Jaenisch R, Tee AR, Sarkar S, Korolchuk VI (2016) Control of TSC2-Rheb signaling axis by arginine regulates mTORC1 activity. eLife. https://doi. org/10.7554/eLife.11058
  76. Swanson JA (2014) Phosphoinositides and engulfment. Cell Microbiol 16(10):1473-1483. https://doi.org/10.1111/cmi.12334
  77. Mayor S, Parton RG, Donaldson JG (2014) Clathrin-independ- ent pathways of endocytosis. Cold Spring Harbor Perspect Biol. https://doi.org/10.1101/cshperspect.a016758
  78. Shibutani S, Okazaki H, Iwata H (2017) Dynamin-dependent amino acid endocytosis activates mechanistic target of rapamycin complex 1 (mTORC1). J Biol Chem. https://doi.org/10.1074/jbc. M117.776443
  79. Li L, Kim E, Yuan H, Inoki K, Goraksha-Hicks P, Schiesher RL, Neufeld TP, Guan KL (2010) Regulation of mTORC1 by the Rab and Arf GTPases. J Biol Chem 285(26):19705-19709. https:// doi.org/10.1074/jbc.C110.102483
  80. Flinn RJ, Yan Y, Goswami S, Parker PJ, Backer JM (2010) The late endosome is essential for mTORC1 signaling. Mol Biol Cell 21(5):833-841. https://doi.org/10.1091/mbc.E09-09-0756
  81. Saci A, Cantley LC, Carpenter CL (2011) Rac1 regulates the activity of mTORC1 and mTORC2 and controls cel- lular size. Mol Cell 42(1):50-61. https://doi.org/10.1016/j. molcel.2011.03.017
  82. Buckley CM, King JS (2017) Drinking problems: mechanisms of macropinosome formation and maturation. Febs J. https://doi. org/10.1111/febs.14115
  83. Yu L, McPhee CK, Zheng L, Mardones GA, Rong Y, Peng J, Mi N, Zhao Y, Liu Z, Wan F, Hailey DW, Oorschot V, Klumperman J, Baehrecke EH, Lenardo MJ (2010) Termination of autophagy and reformation of lysosomes regulated by mTOR. Nature 465(7300):942-946. https://doi.org/10.1038/nature09076
  84. Tan HWS, Sim AYL, Long YC (2017) Glutamine metabolism regulates autophagy-dependent mTORC1 reactivation dur- ing amino acid starvation. Nat Commun 8(1):338. https://doi. org/10.1038/s41467-017-00369-y
  85. Bar-Sagi D, Feramisco JR (1986) Induction of membrane ruf- fling and fluid-phase pinocytosis in quiescent fibroblasts by ras proteins. Science 233(4768):1061-1068
  86. Egami Y, Taguchi T, Maekawa M, Arai H, Araki N (2014) Small GTPases and phosphoinositides in the regulatory mechanisms of macropinosome formation and maturation. Front Physiol 5:374. https://doi.org/10.3389/fphys.2014.00374
  87. Yoshida S, Hoppe AD, Araki N, Swanson JA (2009) Sequential signaling in plasma-membrane domains during macropinosome formation in macrophages. J Cell Sci 122(Pt 18):3250-3261. https://doi.org/10.1242/jcs.053207
  88. Racoosin EL, Swanson JA (1993) Macropinosome maturation and fusion with tubular lysosomes in macrophages. J Cell Biol 121(5):1011-1020
  89. Hewlett LJ, Prescott AR, Watts C (1994) The coated pit and macropinocytic pathways serve distinct endosome populations. J Cell Biol 124(5):689-703
  90. Welliver TP, Chang SL, Linderman JJ, Swanson JA (2011) Ruf- fles limit diffusion in the plasma membrane during macropino- some formation. J Cell Sci 124(Pt 23):4106-4114
  91. de Rooij J, Bos JL (1997) Minimal Ras-binding domain of Raf1 can be used as an activation-specific probe for Ras. Oncogene 14(5):623-625. https://doi.org/10.1038/sj.onc.1201005
  92. Welliver TP, Swanson JA (2012) A growth factor signaling cascade confined to circular ruffles in macrophages. Biol Open 1(8):754-760. https://doi.org/10.1242/bio.20121784
  93. Dubielecka PM, Cui P, Xiong X, Hossain S, Heck S, Angelov L, Kotula L (2010) Differential regulation of macropinocytosis by Abi1/Hssh3bp1 isoforms. PLoS One 5(5):e10430. https://doi. org/10.1371/journal.pone.0010430
  94. Schlunck G, Damke H, Kiosses WB, Rusk N, Symons MH, Waterman-Storer CM, Schmid SL, Schwartz MA (2004) Modu- lation of Rac localization and function by dynamin. Mol Biol Cell 15(1):256-267. https://doi.org/10.1091/mbc.E03-01-0019
  95. Lanzetti L, Palamidessi A, Areces L, Scita G, Di Fiore PP (2004) Rab5 is a signalling GTPase involved in actin remodelling by receptor tyrosine kinases. Nature 429(6989):309-314. https:// doi.org/10.1038/nature02542
  96. Hoon JL, Wong WK, Koh CG (2012) Functions and regulation of circular dorsal ruffles. Mol Cell Biol 32(21):4246-4257. https:// doi.org/10.1128/MCB.00551-12
  97. Itoh T, Hasegawa J (2013) Mechanistic insights into the regula- tion of circular dorsal ruffle formation. J Biochem 153(1):21-29. https://doi.org/10.1093/jb/mvs138
  98. Araki N, Johnson MT, Swanson JA (1996) A role for phospho- inositide 3-kinase in the completion of macropinocytosis and phagocytosis by macrophages. J Cell Biol 135(5):1249-1260
  99. Araki N, Egami Y, Watanabe Y, Hatae T (2007) Phospho- inositide metabolism during membrane ruffling and macropino- some formation in EGF-stimulated A431 cells. Exp Cell Res 313(7):1496-1507. https://doi.org/10.1016/j.yexcr.2007.02.012
  100. Dubielecka PM, Machida K, Xiong X, Hossain S, Ogiue-Ikeda M, Carrera AC, Mayer BJ, Kotula L (2010) Abi1/Hssh3bp1 pY213 links Abl kinase signaling to p85 regulatory subunit of PI-3 kinase in regulation of macropinocytosis in LNCaP cells. FEBS Lett 584(15):3279-3286. https://doi.org/10.1016/j. febslet.2010.06.029
  101. Yoshida S, Gaeta I, Pacitto R, Krienke L, Alge O, Gregorka B, Swanson JA (2015) Differential signaling during macropinocy- tosis in response to M-CSF and PMA in macrophages. Front Physiol 6:8
  102. Liu WS, Heckman CA (1998) The sevenfold way of PKC regula- tion. Cell Signal 10(8):529-542
  103. Ard R, Mulatz K, Pomoransky JL, Parks RJ, Trinkle-Mulcahy L, Bell JC, Gee SH (2015) Regulation of macropinocytosis by diacylglycerol kinase zeta. PLoS One 10(12):e0144942. https:// doi.org/10.1371/journal.pone.0144942
  104. Porat-Shliom N, Kloog Y, Donaldson JG (2008) A unique plat- form for H-Ras signaling involving clathrin-independent endo- cytosis. Mol Biol Cell 19(3):765-775. https://doi.org/10.1091/ mbc.E07-08-0841
  105. Li G, D'Souza-Schorey C, Barbieri MA, Cooper JA, Stahl PD (1997) Uncoupling of membrane ruffling and pinocytosis during Ras signal transduction. J Biol Chem 272(16):10337-10340
  106. Palm W, Araki J, King B, DeMatteo RG, Thompson CB (2017) Critical role for PI3-kinase in regulating the use of proteins as an amino acid source. Proc Natl Acad Sci USA. https://doi. org/10.1073/pnas.1712726114
  107. Wall AA, Luo L, Hung Y, Tong SJ, Condon ND, Blumenthal A, Sweet MJ, Stow JL (2017) Small GTPase Rab8a-recruited phosphatidylinositol 3-kinase gamma regulates signaling and cytokine outputs from endosomal toll-like receptors. J Biol Chem 292(11):4411-4422. https://doi.org/10.1074/jbc.M116.766337
  108. Bloomfield G, Traynor D, Sander SP, Veltman DM, Pachebat JA, Kay RR (2015) Neurofibromin controls macropinocytosis and phagocytosis in Dictyostelium. eLife. https://doi.org/10.7554/ eLife.04940
  109. Veltman DM, Williams TD, Bloomfield G, Chen BC, Betzig E, Insall RH, Kay RR (2016) A plasma membrane template for macropinocytic cups. eLife. https://doi.org/10.7554/eLife.20085
  110. Swanson JA (1989) Phorbol esters stimulate macropinocy- tosis and solute flow through macrophages. J Cell Sci 94(Pt 1):135-142
  111. Koivusalo M, Welch C, Hayashi H, Scott CC, Kim M, Alexander T, Touret N, Hahn KM, Grinstein S (2010) Amiloride inhibits macropinocytosis by lowering submembranous pH and prevent- ing Rac1 and Cdc42 signaling. J Cell Biol 188(4):547-563. https://doi.org/10.1083/jcb.200908086
  112. Marat AL, Haucke V (2016) Phosphatidylinositol 3-phos- phates-at the interface between cell signalling and membrane traffic. EMBO J 35(6):561-579. https://doi.org/10.15252/ embj.201593564
  113. Shisheva A (2008) PIKfyve: partners, significance, debates and paradoxes. Cell Biol Int 32(6):591-604. https://doi.org/10.1016/j. cellbi.2008.01.006
  114. Bridges D, Ma JT, Park S, Inoki K, Weisman LS, Saltiel AR (2012) Phosphatidylinositol 3,5-bisphosphate plays a role in the activation and subcellular localization of mechanistic target of rapamycin 1. Mol Biol Cell 23(15):2955-2962. https://doi. org/10.1091/mbc.E11-12-1034
  115. Robinson FL, Dixon JE (2006) Myotubularin phosphatases: policing 3-phosphoinositides. Trends Cell Biol 16(8):403-412. https://doi.org/10.1016/j.tcb.2006.06.001
  116. Hao F, Itoh T, Morita E, Shirahama-Noda K, Yoshimori T, Noda T (2016) The PtdIns3-phosphatase MTMR3 interacts with mTORC1 and suppresses its activity. FEBS Lett 590(1):161-173. https://doi.org/10.1002/1873-3468.12048
  117. Erami Z, Khalil BD, Salloum G, Yao Y, LoPiccolo J, Shymanets A, Nurnberg B, Bresnick AR, Backer JM (2017) Rac1-stimulated macropinocytosis enhances Gβγ activation of PI3Kβ. Biochem J. https://doi.org/10.1042/BCJ20170279
  118. Nada S, Hondo A, Kasai A, Koike M, Saito K, Uchiyama Y, Okada M (2009) The novel lipid raft adaptor p18 controls endo- some dynamics by anchoring the MEK-ERK pathway to late endosomes. EMBO J 28(5):477-489. https://doi.org/10.1038/ emboj.2008.308
  119. Kamphorst JJ, Nofal M, Commisso C, Hackett SR, Lu W, Grab- ocka E, Vander Heiden MG, Miller G, Drebin JA, Bar-Sagi D, Thompson CB, Rabinowitz JD (2015) Human pancreatic cancer tumors are nutrient poor and tumor cells actively scav- enge extracellular protein. Can Res 75(3):544-553. https://doi. org/10.1158/0008-5472.CAN-14-2211
  120. Tajiri H, Uruno T, Shirai T, Takaya D, Matsunaga S, Setoyama D, Watanabe M, Kukimoto-Niino M, Oisaki K, Ushijima M, Sanematsu F, Honma T, Terada T, Oki E, Shirasawa S, Maehara Y, Kang D, Cote JF, Yokoyama S, Kanai M, Fukui Y (2017) Targeting Ras-driven cancer cell survival and invasion through selective inhibition of DOCK1. Cell Rep 19(5):969-980. https:// doi.org/10.1016/j.celrep.2017.04.016
  121. Pavlova NN, Thompson CB (2016) The emerging hallmarks of cancer metabolism. Cell Metab 23(1):27-47. https://doi. org/10.1016/j.cmet.2015.12.006
  122. Nofal M, Zhang K, Han S, Rabinowitz JD (2017) mTOR inhibi- tion restores amino acid balance in cells dependent on catabolism of extracellular protein. Mol Cell 67(6):936-946 e935. https:// doi.org/10.1016/j.molcel.2017.08.011
  123. Nathan N, Keppler-Noreuil KM, Biesecker LG, Moss J, Dar- ling TN (2017) Mosaic disorders of the PI3K/PTEN/AKT/TSC/ mTORC1 signaling pathway. Dermatol Clin 35(1):51-60. https:// doi.org/10.1016/j.det.2016.07.001

Related papers

Combined mTORC1/mTORC2 inhibition blocks growth and induces catastrophic macropinocytosis in cancer cells
Nilam Banerjee

Proceedings of the National Academy of Sciences, 2019

Significance We report that cell lines of rhabdomyosarcoma (RMS) and cancer cell lines of skin, breast, lung, and cervix are highly sensitive to mTORC1/2 dual inhibitors. mTORC1/2 complexes regulate protein synthesis, cell proliferation, growth, stress responses and survival. The cancer cells died by a catastrophic process, called macropinocytosis, in which numerous single-membrane vacuoles filled with watery fluid formed, merged, and ruptured, killing the cells. Consistent with the findings in cultured cells, the growth of RMS cells implanted in immunocompromised mice was significantly reduced, especially in combination with cyclophosphamide, a standard chemotherapeutic drug to treat RMS.

View PDFchevron_right
Hyperactivation of Mammalian Target of Rapamycin Complex 1 (mTORC1) Promotes Breast Cancer Progression through Enhancing Glucose Starvation-induced Autophagy and Akt Signaling
Yongqiang Chen

Journal of Biological Chemistry, 2013

Background: TSC1 is a negative regulator for mTORC1 that is implicated in cancer. Results: mTORC1 activation by TSC1 deletion promotes mammary tumor growth through increasing autophagy and Akt activation of tumor cells. Conclusion: mTORC1 activation in mammary tumor cells is important in promoting breast cancer progression in vivo. Significance: New insights into the mechanisms of breast cancer progression may offer potential targets in breast cancer therapy.

View PDFchevron_right
Ral and Rheb GTPase Activating Proteins Integrate mTOR and GTPase Signaling in Aging, Autophagy, and Tumor Cell Invasion
Alan Saltiel

Molecular Cell, 2014

View PDFchevron_right
mTORC1 inhibition in cancer cells protects from glutaminolysis-mediated apoptosis during nutrient limitation
Victor Villar

A master coordinator of cell growth, mTORC1 is activated by different metabolic inputs, particularly the metabolism of glutamine (glutaminolysis), to control a vast range of cellular processes, including autophagy. As a well-recognized tumour promoter, inhibitors of mTORC1 such as rapamycin have been approved as anti-cancer agents, but their overall outcome in patients is rather poor. Here we show that mTORC1 also presents tumour suppressor features in conditions of nutrient restrictions. Thus, the activation of mTORC1 by glutaminolysis during nutritional imbalance inhibits autophagy and induces apoptosis in cancer cells. Importantly, rapamycin treatment reactivates autophagy and prevents the mTORC1-mediated apoptosis. We also observe that the ability of mTORC1 to activate apoptosis is mediated by the adaptor protein p62. Thus, the mTORC1-mediated upregulation of p62 during nutrient imbalance induces the binding of p62 to caspase 8 and the subsequent activation of the caspase pathway. Our data highlight the role of autophagy as a survival mechanism upon rapamycin treatment.

View PDFchevron_right
mTOR and autophagy: a dynamic relationship governed by nutrients and energy
Elaine Dunlop

Seminars in cell & developmental biology, 2014

Mechanistic target of rapamycin (mTOR) functions as a key homeostatic regulator of cell growth and orchestrates whether anabolic or catabolic reactions are favoured. mTOR complex 1 (mTORC1) manages multiple biosynthetic pathways and promotes cell growth when nutrients are in plentiful supply. Many advances have been made over the last decade on nutrient sensing centred on mTORC1. Recent research reveals that mTORC1 maintains nutrient homeostasis through lysosomal biogenesis and autophagic processes. Cells utilise autophagy to recycle damaged or unwanted organelles and macromolecules and in so doing, generate energy and recover precursor building blocks necessary for normal growth. It is clear that mTOR and autophagy are closely integrated within cells, where defects in signalling through both pathways are known to drive the onset of a range of human diseases, such as cancer and neurodegenerative disease. This review focuses on the dynamic signalling interplay between mTOR and autoph...

View PDFchevron_right

Related topics

  • Physiology
  • Chemistry
  • Biology
  • Cell Biology
  • Medicine
  • Biochemistry and cell biology

    • Cited by

    Constitutive and stimulated macropinocytosis in macrophages: roles in immunity and in the pathogenesis of atherosclerosis
    Sasha Doodnauth

    Philosophical Transactions of the Royal Society B: Biological Sciences

    Macrophages respond to several stimuli by forming florid membrane ruffles that lead to fluid uptake by macropinocytosis. This type of induced macropinocytosis, executed by a variety of non-malignant and malignant cells, is initiated by transmembrane receptors and is involved in nutrient acquisition and mTOR signalling. However, macrophages also perform a unique type of constitutive ruffling and macropinocytosis that is dependent on the presence of extracellular calcium. Calcium-sensing receptors are responsible for this activity. This distinct form of macropinocytosis enables macrophages to continuously sample their microenvironment for antigenic molecules and for pathogen- and danger-associated molecular patterns, as part of their immune surveillance functions. Interestingly, even within the monocyte lineage, there are differences in macropinocytic ability that reflect the polarized functional roles of distinct macrophage subsets. This review discusses the shared and distinct featu...

    View PDFchevron_right
    Peptide-Based Drug Delivery Systems
    Arman Saparov

    Medicina

    Peptide-based drug delivery systems have many advantages when compared to synthetic systems in that they have better biocompatibility, biochemical and biophysical properties, lack of toxicity, controlled molecular weight via solid phase synthesis and purification. Lysosomes, solid lipid nanoparticles, dendrimers, polymeric micelles can be applied by intravenous administration, however they are of artificial nature and thus may induce side effects and possess lack of ability to penetrate the blood-brain barrier. An analysis of nontoxic drug delivery systems and an establishment of prospective trends in the development of drug delivery systems was needed. This review paper summarizes data, mainly from the past 5 years, devoted to the use of peptide-based carriers for delivery of various toxic drugs, mostly anticancer or drugs with limiting bioavailability. Peptide-based drug delivery platforms are utilized as peptide–drug conjugates, injectable biodegradable particles and depots for d...

    View PDFchevron_right
    Differential regulation of mTORC1 activation by leucine and β-hydroxy-β-methylbutyrate in skeletal muscle of neonatal pigs
    Teresa Davis

    Journal of Applied Physiology

    Leucine (Leu) and its metabolite β-hydroxy-β-methylbutyrate (HMB) stimulate mechanistic target of rapamycin (mTOR) complex 1 (mTORC1)-dependent protein synthesis in the skeletal muscle of neonatal pigs. This study aimed to determine whether HMB and Leu utilize common nutrient-sensing mechanisms to activate mTORC1. In study 1, neonatal pigs were fed one of five diets for 24 h: low protein (LP), high protein (HP), or LP supplemented with 4 (LP+HMB4), 40 (LP+HMB40), or 80 (LP+HMB80) μmol HMB·kg body wt−1·day−1. In study 2, neonatal pigs were fed for 24 h: LP, LP supplemented with Leu (LP+Leu), or HP diets delivering 9, 18, and 18 mmol Leu·kg body wt−1·day−1, respectively. The upstream signaling molecules that regulate mTORC1 activity were analyzed. mTOR phosphorylation on Ser2448 and Ser2481 was greater in LP+HMB40, LP+HMB80, and LP+Leu than in LP and greater in HP than in HMB-supplemented groups ( P < 0.05), whereas HP and LP+Leu were similar. Rheb-mTOR complex formation was lower ...

    View PDFchevron_right
    Is cell migration a selectable trait in the natural evolution of cancer development?
    Abrar Rizvi

    Philosophical Transactions of the Royal Society B: Biological Sciences, 2019

    Selective evolutionary pressure shapes the processes and genes that enable cancer survival and expansion in a tumour-suppressive environment. A distinguishing lethal feature of malignant cancer is its dissemination and seeding of metastatic foci. A key requirement for this process is the acquisition of a migratory/invasive ability. However, how the migratory phenotype is selected for during the natural evolution of cancer and what advantage, if any, it might provide to the growing malignant cells remain open issues. In this opinion piece, we discuss three possible answers to these issues. We will examine lines of evidence from mathematical modelling of cancer evolution that indicate that migration is an intrinsic selectable property of malignant cells that directly impacts on growth dynamics and cancer geometry. Second, we will argue that migratory phenotypes can emerge as an adaptive response to unfavourable growth conditions and endow cells not only with the ability to move/invade...

    View PDFchevron_right
    A novel form of macropinocytosis mediates ultra-rapid transfer of pathological alpha-synuclein to lysosomes
    Chanshuai Han

    2022

    The nervous system spread of alpha-synuclein fibrils leads to Parkinson’s disease (PD) and other synucleinopathies, yet the mechanisms underlying internalization and cell-to-cell transfer are enigmatic. Here we use confocal and superresolution microscopy, subcellular fractionation and electron microscopy (EM) of immunogold labelled alpha-synuclein pre-formed fibrils (PFF) to demonstrate that this toxic protein species enters cells using a novel form of ultra-rapid macropinocytosis with transfer to lysosomes in as little as 2 minutes, an unprecedented cell biological kinetic for lysosomal targeting. PFF uptake circumvents classical endosomal pathways and is independent of clathrin. Immunogold-labelled PFF are seen at the highly curved inward edge of membrane ruffles, in newly formed macropinosomes, and in lysosomes. While many of the fibrils remain in lysosomes that continue to take up PFF for hours, a portion are transferred to neighboring naïve cells on the external face of vesicle...

    View PDFchevron_right
    580 California St., Suite 400
    San Francisco, CA, 94104
    © 2025 Academia. All rights reserved